A Phase 3 interventional study of TAP-144-SR(6M) and TAP-144-SR(3M) in Prostate Cancer, sponsored by Takeda. Completed at 16 sites in Japan. Open to male participants aged 20 Years to 85 Years. Per ClinicalTrials.gov, last updated 2015-07-21.
Sponsored by Takeda · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing leuprolide in Prostatic Neoplasms — 9 open to participants now, 16 under way, 6 of them phase 3. Leuprolide · Prostatic Neoplasms.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, this one is the 18th largest by enrollment of the 69 interventional ones that give a count, is the only one that started in 2012, is one of 26 in phase 3, and was the 31st registered.
7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →9 of the 70 studies testing leuprolide in Prostatic Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
Baptist Health South Florida · Sites in United States
Ages 18+ · Men only
Ontario Clinical Oncology Group (OCOG) · Sites in Canada
Ages 18+ · Men only
Emory University · Sites in United States
Ages 18+ · Men only
Ohio State University Comprehensive Cancer Center · Sites in United States
Ages 18+ · Men only
Cancer Research Antwerp · Sites in Belgium
Ages 18+ · Men only
By country, each count listing its studies:
Leuprolide: first FDA approval 1985 (LUPRON), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 20 Years to 85 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 26 · Phase 3 27 · Phase 4 9
First in 1994; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 160 is above the median of 60 across 5,352 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 77 across the 69 interventional studies. Of the 47 that completed or were terminated, 26 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 70 have an industry lead sponsor. The 10 most frequent:
Takeda is the lead sponsor of 1,026 studies on the registry; 88 are open to participants now.
Of its 178 completed or terminated interventional studies of FDA-regulated products, 154 (87%) have results posted.
22 studies in Prostatic Neoplasms by Takeda: none open now, none under way, none of them phase 3. Of 22 finished, 13 (59%) have results posted.
Among the 22 studies in Prostatic Neoplasms by Takeda, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 3 that started in 2012, is one of 5 in phase 3, and was the 13th registered.
Takeda’s Prostatic Neoplasms studies by the year they started, since 1996.
7 of the studies testing leuprolide in Prostatic Neoplasms that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05169112Phase 3Ottawa Hospital Research InstituteImpact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy | 2026-11 |
| NCT04302454Phase 3University Medical Center GroningenAndrogen Deprivation Therapy for Oligo-recurrent Prostate Cancer in Addition to radioTherapy | 2027-10-21 |
| NCT06627530Brazilian Clinical Research InstituteCOACTION Trial - COmbination Androgen bloCkade in inTermediate to hIgh-risk prOstate caNcer | 2026-12 |
| NCT04249154McGill University Health Centre/Research Institute of the McGill University Health CentrePostop Hypofractionated Radiation Therapy and LHRH in Patients With Prostate Cancer | 2026-12-15 |
| NCT03902951Jonsson Comprehensive Cancer CenterAntiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer | 2027-01-01 |
Add all 7 to your calendar (.ics) → With an account.
Among the 70 studies testing leuprolide in Prostatic Neoplasms, from their registry updates:
Among Takeda’s 22 in Prostatic Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate hormone dynamics, pharmacokinetics, safety, and efficacy of TAP-144-SR(6M) against TAP-144-SR(3M) in prostate cancer patients previously treated with hormonal therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
(1) Renal function: serum creatinine level\< 1.5 times the (ULN) (2) Bone-marrow function: white blood count ≥ 3,500/ mm3, count ≥ 100,000/L, ≥ 10.0g/dL (3) Hepatic function: (GOT), ALT(GPT), ALP and total ≤ 2.5 times the ULN 10. The participant's is at least 24 months at .
Exclusion Criteria:
(1) Radiotherapy. As for I-125 brachytherapy, within 35 weeks (245 days) prior to study enrollment.
(2) Prostatectomy (3) Experimental therapy including high-intensity focused ultrasound therapy (HIFU), immunotherapy, and gene therapy 11. Patients who received the following drugs within 4 weeks (28 days) before starting the study drug: Testosterones, ketoconazole(except for external preparations), spironolactone, corticosteroids (excluding their inhalants and external preparations), and Chinese medicines and dietary supplements containing saw palmetto 12. Patients whose interval exceeded 460 msec on the 12-lead at screening 13. The participant has a history of to synthetic LHRH, LHRH derivative or any component of the study drug.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TAP-144-SR(6M) 22.5 mg, injection, treatment interval 24 weeks for up to 48 weeks.
Drug: TAP-144-SR(6M)
TAP-144-SR(3M) 11.25 mg, injection, treatment interval 12 weeks for up to 48 weeks.
Drug: TAP-144-SR(3M)
The Rate of Suppression of Serum Testosterone to Castrate Level
Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)
Time frame: From the start of study drug administration through Week 48
Time Course of Changes in Serum Testosterone
Time frame: From baseline to Week 48
Time Course of Changes in Serum Luteinizing Hormone (LH)
Time frame: From baseline to Week 48
Time Course of Changes in Serum Follicle-stimulating Hormone (FSH)
Time frame: From baseline to Week 48
Time Course of Change Rate in Serum PSA (FAS)
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen \[PSA\])
Time frame: From baseline to Week 48
The Maximum Rate of Change in PSA Suppression (FAS)
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)
Time frame: From baseline to Week 48
Percentage of Participants With Progression by PSA (FAS)
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)
Time frame: From baseline to Week 48
Soft Tissue Response
Assessment in accordance with the "criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
Time frame: At week 48
Bone Lesion Response
Partially revised assessment based on the "criteria for therapeutic effect" from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression
Time frame: At Week 48
Serum Unchanged TAP-144 Level
Time frame: From baseline to Week 48
12-lead ECG
Time frame: At 1 hour, week 24, and week 48 after administration
Participants took part in the study at 23 investigative sites in Japan from 11 April 2012 to 04 April 2014.
| Milestone | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Started | 82 | 80 |
| Received study drug | 81 | 79 |
| Completed | 76 | 74 |
| Not completed | 6 | 6 |
| Withdrew: Adverse event | 2 | 3 |
| Withdrew: Major protocol deviation | 1 | 1 |
| Withdrew: High prostate specific antigen | 2 | 1 |
| Withdrew: Did not receive study drug | 1 | 1 |
Comparison of the proportion of patients maintained at castration level (≤100 ng/dL)
| Participants | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Number of participants maintained | 81 | 78 |
| Number of participants who did not maintain | 0 | 1 |
| ng/dL | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Baseline | 8.0 (0 to 33) | 7.0 (0 to 388) |
| Week 1 | 6.0 (0 to 33) | 7.0 (0 to 267) |
| Week 2 | 7.0 (0 to 37) | 6.0 (0 to 55) |
| Week 4 | 7.0 (0 to 35) | 8.0 (0 to 33) |
| Week 8 | 7.5 (0 to 53) | 8.0 (0 to 33) |
| Week 12 | 7.0 (0 to 41) | 8.0 (0 to 36) |
| Week 16 | 7.0 (0 to 45) | 7.5 (0 to 34) |
| Week 20 | 8.0 (0 to 43) | 6.0 (0 to 40) |
| Week 24 | 7.0 (0 to 37) | 6.0 (0 to 33) |
| Week 25 | 6.0 (0 to 30) | 5.5 (0 to 30) |
| Week 26 | 5.0 (0 to 35) | 4.0 (0 to 32) |
| Week 28 | 8.0 (0 to 36) | 6.0 (0 to 36) |
| Week 32 | 9.0 (0 to 41) | 8.0 (0 to 30) |
| Week 36 | 8.0 (0 to 34) | 7.0 (0 to 40) |
| Week 40 | 8.0 (0 to 39) | 8.0 (0 to 37) |
| Week 44 | 7.0 (0 to 37) | 8.0 (0 to 33) |
| Week 48 | 9.0 (0 to 42) | 6.0 (0 to 34) |
| mIU/mL | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Baseline | 0.000 (0.00 to 1.44) | 0.000 (0.00 to 12.25) |
| Week 1 | 0.160 (0.00 to 1.03) | 0.220 (0.00 to 7.57) |
| Week 2 | 0.180 (0.00 to 0.68) | 0.150 (0.00 to 2.91) |
| Week 4 | 0.120 (0.00 to 0.37) | 0.110 (0.00 to 0.65) |
| Week 8 | 0.000 (0.00 to 0.33) | 0.000 (0.00 to 0.67) |
| Week 12 | 0.000 (0.00 to 0.35) | 0.110 (0.00 to 1.56) |
| Week 16 | 0.000 (0.00 to 0.38) | 0.055 (0.00 to 0.87) |
| Week 20 | 0.000 (0.00 to 0.36) | 0.110 (0.00 to 0.58) |
| Week 24 | 0.000 (0.00 to 1.38) | 0.000 (0.00 to 0.63) |
| Week 25 | 0.150 (0.00 to 0.67) | 0.185 (0.00 to 0.54) |
| Week 26 | 0.170 (0.00 to 0.84) | 0.130 (0.00 to 0.48) |
| Week 28 | 0.110 (0.00 to 0.35) | 0.000 (0.00 to 0.59) |
| Week 32 | 0.000 (0.00 to 0.26) | 0.000 (0.00 to 0.66) |
| Week 36 | 0.000 (0.00 to 0.24) | 0.000 (0.00 to 0.76) |
| Week 40 | 0.000 (0.00 to 0.31) | 0.000 (0.00 to 0.49) |
| Week 44 | 0.000 (0.00 to 0.32) | 0.000 (0.00 to 0.66) |
| Week 48 | 0.000 (0.00 to 0.42) | 0.000 (0.00 to 0.84) |
| mIU/mL | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Baseline | 5.120 (1.93 to 13.31) | 4.780 (2.02 to 18.52) |
| Week 1 | 5.430 (1.87 to 15.52) | 4.810 (1.77 to 17.62) |
| Week 2 | 4.890 (1.99 to 13.12) | 4.710 (1.81 to 16.40) |
| Week 4 | 4.625 (1.72 to 14.11) | 4.950 (1.49 to 16.19) |
| Week 8 | 5.225 (1.90 to 13.75) | 5.240 (1.79 to 17.23) |
| Week 12 | 5.340 (2.24 to 14.04) | 5.110 (1.86 to 15.97) |
| Week 16 | 5.300 (2.07 to 13.87) | 5.370 (1.81 to 15.65) |
| Week 20 | 5.030 (1.65 to 12.21) | 5.260 (1.91 to 15.01) |
| Week 24 | 4.990 (1.97 to 13.45) | 5.150 (2.12 to 16.47) |
| Week 25 | 5.210 (2.16 to 12.92) | 4.970 (1.84 to 17.02) |
| Week 26 | 5.010 (2.34 to 13.14) | 5.020 (1.96 to 14.69) |
| Week 28 | 5.060 (2.31 to 13.38) | 5.070 (2.05 to 13.63) |
| Week 32 | 5.210 (2.32 to 13.20) | 5.030 (2.08 to 12.54) |
| Week 36 | 5.585 (2.01 to 13.00) | 4.970 (2.09 to 14.08) |
| Week 40 | 5.100 (1.80 to 14.85) | 4.910 (2.05 to 13.20) |
| Week 44 | 5.150 (1.69 to 12.90) | 4.990 (2.17 to 14.14) |
| Week 48 | 5.110 (1.44 to 11.69) | 4.820 (2.18 to 14.46) |
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by prostate-specific antigen \[PSA\])
| percent change | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Week 4 | -7.930 (-100.00 to 181.82) | -10.000 (-100.00 to 122.95) |
| Week 8 | -14.255 (-100.00 to 190.06) | -15.880 (-100.00 to 184.85) |
| Week 12 | -20.810 (-100.00 to 360.84) | -21.130 (-100.00 to 754.55) |
| Week 16 | -19.720 (-100.00 to 634.69) | -20.650 (-100.00 to 1866.67) |
| Week 20 | -44.740 (-100.00 to 932.65) | -39.970 (-100.00 to 3718.18) |
| Week 24 | -49.270 (-100.00 to 2002.04) | -31.110 (-100.00 to 9900.00) |
| Week 28 | -56.705 (-100.00 to 2920.41) | -45.875 (-100.00 to 15354.55) |
| Week 32 | -57.690 (-100.00 to 7389.80) | -40.745 (-100.00 to 21051.52) |
| Week 36 | -60.710 (-100.00 to 9675.51) | -50.520 (-100.00 to 23506.06) |
| Week 40 | -80.610 (-100.00 to 5348.98) | -58.520 (-100.00 to 21627.27) |
| Week44 | -74.105 (-100.00 to 6859.18) | -54.585 (-100.00 to 24506.06) |
| Week 48 | -72.900 (-100.00 to 6818.37) | -59.400 (-100.00 to 22839.39) |
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)
| percent change | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| The Maximum Rate of Change in PSA Suppression (FAS) | -86.225 (-100.00 to 108.73) | -67.030 (-100.00 to 75.76) |
Evaluation according to the "Criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition (determination of therapeutic effect by PSA)
| percentage of participants | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Presence of disesase progression: Yes | 7.5 | 92.5 |
| Presence of disesase progression: No | 6.5 | 93.5 |
Assessment in accordance with the "criteria for therapeutic effect" from the General Rule for Clinical Pathological Studies on Prostate Cancer, 4th edition. Soft tissue response was evaluated in accordance with the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by CT or MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.
| Percentage of participants | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Complete response | 0.0 | 0.0 |
| Partial Response | 0.0 | 0.0 |
| Stable Disease | 13.9 | 11.8 |
| Progressive Disease | 0.0 | 2.6 |
| Not Evaluable | 86.1 | 85.5 |
Partially revised assessment based on the "criteria for therapeutic effect" from the General Rule for Clinical and Pathological Studies on Prostate Canter, 4th edition. Response is measured using bone scintigraphy. Increase in new (2 or more) bone lesion is considered as progression
| Percentage of participants | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Presence of disesase progression: New lesions ≥ 2 | 1.3 | 1.3 |
| Presence of disesase progression: New lesions < 1 | 98.7 | 98.7 |
| ng/dL | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Baseline | 0.07113 ± 0.043808 | 0.06188 ± 0.035339 |
| Week 1 | 0.1304 ± 0.16388 | 0.1869 ± 0.077198 |
| Week 2 | 0.3085 ± 0.30523 | 0.1335 ± 0.083060 |
| Week 4 | 0.8845 ± 0.52695 | 0.1132 ± 0.12110 |
| Week 8 | 0.1792 ± 0.10354 | 0.08374 ± 0.041078 |
| Week 12 | 0.1256 ± 0.068860 | 0.08039 ± 0.056305 |
| Week 16 | 0.1024 ± 0.093951 | 0.1220 ± 0.067137 |
| Week 20 | 0.06957 ± 0.053682 | 0.08450 ± 0.039532 |
| Week 24 | 0.05167 ± 0.043221 | 0.07437 ± 0.045186 |
| Week 25 | 0.1353 ± 0.29809 | 0.1978 ± 0.083286 |
| Week 26 | 0.4318 ± 0.63101 | 0.1418 ± 0.087312 |
| Week 28 | 0.7622 ± 0.42483 | 0.1067 ± 0.054505 |
| Week 32 | 0.1524 ± 0.098308 | 0.08236 ± 0.046180 |
| Week 36 | 0.1091 ± 0.057582 | 0.08407 ± 0.075147 |
| Week 40 | 0.09118 ± 0.065771 | 0.1086 ± 0.051455 |
| Week 44 | 0.06958 ± 0.055624 | 0.08639 ± 0.051923 |
| Week 48 | 0.04596 ± 0.030006 | 0.07945 ± 0.066980 |
| msec | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| QTcF interval measurement at Basline | 429.0 ± 15.75 | 436.2 ± 15.63 |
| QTcF interval measurement at 1 hour | 422.2 ± 20.80 | 432.2 ± 21.93 |
| QTcF interval measurement at Week 24 | 425.0 ± 20.01 | 433.4 ± 18.91 |
| QTcF interval measurement at Week 48 | 428.1 ± 16.42 | 431.7 ± 16.05 |
Collected over From the first dose of study drug until 14 days (or 30 days for a serious adverse event) after the last dose of open-label study drug (up to 56 weeks).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TAP-144-SR(6M) | — | 10/81 (12.3%) | 74/81 (91.4%) |
| TAP-144-SR(3M) | — | 8/79 (10.1%) | 71/79 (89.9%) |
| Event | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| Inguinal herniaGastrointestinal disorders | 1/81 | 1/79 |
| Lung adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/81 | 1/79 |
| Bladder cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/81 | 1/79 |
| Gastric cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/81 | 1/79 |
| Diabetes mellitusMetabolism and nutrition disorders | 0/81 | 1/79 |
| Peripheral arterial occlusive diseaseVascular disorders | 0/81 | 1/79 |
| Calculus bladderRenal and urinary disorders | 0/81 | 1/79 |
| Appendicitis perforatedInfections and infestations | 0/81 | 1/79 |
| Disuse syndromeGeneral disorders | 0/81 | 1/79 |
| CataractEye disorders | 0/81 | 1/79 |
| Event | TAP-144-SR(6M) | TAP-144-SR(3M) |
|---|---|---|
| NasopharyngitisInfections and infestations | 18/81 | 25/79 |
| Injection site indurationGeneral disorders | 14/81 | 11/79 |
| Injection site erythemaGeneral disorders | 12/81 | 6/79 |
| Back painMusculoskeletal and connective tissue disorders | 2/81 | 8/79 |
| Blood creatine phosphokinase increasedInvestigations | 5/81 | 7/79 |
| Dental cariesGastrointestinal disorders | 6/81 | 1/79 |
| Injection site painGeneral disorders | 6/81 | 5/79 |
| FallInjury, poisoning and procedural complications | 6/81 | 3/79 |
| ContusionInjury, poisoning and procedural complications | 6/81 | 1/79 |
| ConstipationGastrointestinal disorders | 3/81 | 5/79 |
The population included all participants who were randomized to treatment.
| Age, Continuous(Years) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| Mean | 73.3 ± 6.32 | 72.6 ± 6.49 | 73.0 ± 6.39 |
| Sex: Female, Male(Participants) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 82 | 80 | 162 |
| Weight(kg) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| Mean | 64.03 ± 8.689 | 65.83 ± 8.098 | 64.92 ± 8.424 |
| Body Mass Index (BMI)(kg/m^2) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| Mean | 23.61 ± 2.731 | 24.32 ± 2.769 | 23.96 ± 2.764 |
| Gleason Score(Participants) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| 2 | 0 ± 0.0 | 0 ± 0.0 | 0 |
| 3 | 0 ± 0.0 | 0 ± 0.0 | 0 |
| 4 | 0 ± 0.0 | 0 ± 0.0 | 0 |
| 5 | 2 ± 2.4 | 2 ± 2.5 | 4 |
| 6 | 8 ± 9.8 | 7 ± 8.8 | 15 |
| 7 | 35 ± 42.7 | 29 ± 36.3 | 64 |
| 8 | 14 ± 17.1 | 21 ± 26.3 | 35 |
| 9 | 20 ± 24.4 | 21 ± 26.3 | 41 |
| 10 | 3 ± 3.7 | 0 | 3 |
| Tumor-node-metastasis (TNM) classification at diagnosis: T(Participants) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| T0 | 0 ± 0.0 | 0 ± 0.0 | 0 |
| T1 | 17 ± 20.7 | 16 ± 20.3 | 33 |
| T2 | 32 ± 39.0 | 24 ± 30.4 | 56 |
| T3 | 29 ± 35.4 | 33 ± 41.8 | 62 |
| T4 | 4 ± 4.9 | 6 ± 7.6 | 10 |
| TX | 0 ± 0.0 | 0 ± 0.0 | 0 |
| Unknown | 0 ± 0 | 0 ± 0.0 | 0 |
| TNM classification at diagnosis: N(Participant) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| N0 | 69 | 62 | 131 |
| N1 | 13 | 17 | 30 |
| NX | 0 | 0 | 0 |
| Unknown | 0 | 0 | 0 |
| TNM classification at diagnosis: M(participants) | TAP-144-SR(6M) | TAP-144-SR(3M) | Total |
|---|---|---|---|
| M0 | 63 | 62 | 125 |
| M1 | 19 | 17 | 36 |
| Unknown | 0 | 0 | 0 |
3 further baseline measures are reported on the registry.
The record gives a start of Mar 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2015, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Leuprolide